ENXTPA:SANPharmaceuticals
Assessing Sanofi (ENXTPA:SAN) Valuation After Dupixent Approval And Respiratory Pipeline Progress
Dupixent approval puts Sanofi’s dermatology franchise in focus
The latest catalyst for Sanofi (ENXTPA:SAN) is the European Commission’s approval of Dupixent in younger children with chronic spontaneous urticaria, which extends an existing indication and draws investor attention to the company’s broader pipeline progress.
See our latest analysis for Sanofi.
Sanofi’s recent Dupixent approval in Europe, positive phase 2 readouts for lunsekimig in respiratory conditions, and its new role with...